Iron Metabolism Markers and Lower Extremity Arterial Disease in People with Type 2 Diabetes

References

• Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellit. 2021;37(04):311–398.
   Google Scholar
• Saeedi P, Petersohn I, Salpea P; et al.; IDF diabetes atlas committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Lu X, Sun J, Bai JJ, Ming Y, Chen LR. Investigation and analysis of lower extremity arterial disease in hospitalized elderly type 2 diabetic patients. Int J Nurs Sci. 2018;5(1):45–49. doi:10.1016/j.ijnss.2017.10.020
   Web of Science ®Google Scholar
• Guan H, Li YJ, Xu ZR, et al. Prevalence and risk factors of peripheral arterial disease in diabetic patients over 50 years old in China. Chin Med Sci J. 2007;22(2):83–88.
   PubMedGoogle Scholar
• Adler A, Stevens R, Neil A, Irene MS, Andrew JMB, Rury RH. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002;25:894–899. doi:10.2337/diacare.25.5.894
   PubMed Web of Science ®Google Scholar
• Wang Z, Fang S, Ding S, Tan Q, Zhang X. Research progress on relationship between iron overload and lower limb arterial disease in type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2022;15:2259–2264. doi:10.2147/DMSO.S366729
   Web of Science ®Google Scholar
• Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811–7819. doi:10.1074/jbc.M008923200
   PubMed Web of Science ®Google Scholar
• Afsar RE, Kanbay M, Ibis A, Afsar B. In-depth review: is hepcidin a marker for the heart and the kidney? Mol Cell Biochem. 2021;476(9):3365–3381. doi:10.1007/s11010-021-04168-4
   PubMed Web of Science ®Google Scholar
• Liu J, Li Q, Yang Y, Ma L. Iron metabolism and type 2 diabetes mellitus: a meta-analysis and systematic review. J Diabetes Investig. 2020;11(4):946–955. doi:10.1111/jdi.13216
   Web of Science ®Google Scholar
• Vela D, Sopi RB, Mladenov M. Low hepcidin in type 2 diabetes mellitus: examining the molecular links and their clinical implications. Can J Diabetes. 2018;42(2):179–187. doi:10.1016/j.jcjd.2017.04.007
   Web of Science ®Google Scholar
• Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093. doi:10.1126/science.1104742
   PubMed Web of Science ®Google Scholar
• Sebastian G, Wilkinso N, Pantopoulo K. Pharmacological targeting of the hepcidin/ferroportin axis. Front Pharmacol. 2016;7:160. doi:10.3389/fphar.2016.00160
   Web of Science ®Google Scholar
• Wunderer F, Traeger L, Sigurslid HH, Meybohm P, Bloch DB, Malhotra R. The role of hepcidin and iron homeostasis in atherosclerosis. Pharmacol Res. 2020;153:104664. doi:10.1016/j.phrs.2020.104664
   PubMed Web of Science ®Google Scholar
• Chinese Diabetes Soiety, Chinese Society of Infectious Diseases, Chinese Society for Tissue Repair and Regeneration. Chinese guideline on prevention and management of diabetic foot (2019 edition) (II). Chin J Diabetes Mellitus. 2019;11(3). doi:10.3760/cma.j.issn.1674-5809.2019.03.005
   Google Scholar
• Alqahtani KM, Bhangoo M, Vaida F, Denenberg JO, Allison MA, Criqui MH. Predictors of change in the ankle brachial index with exercise. Eur J Vasc Endovasc Surg. 2018;55(3):399–404. doi:10.1016/j.ejvs.2017.12.004
   Web of Science ®Google Scholar
• Zhang X, Ran X, Xu Z, et al. Epidemiological characteristics of lower extremity arterial disease in Chinese diabetes patients at high risk: a prospective, multicenter, cross-sectional study. J Diabetes Complications. 2018;32(2):150–156. doi:10.1016/j.jdiacomp.2017.10.003
   PubMed Web of Science ®Google Scholar
• Ban YJ, Ran XW, Yang C, et al. Comparison of clinical characteristics and medical costs of patients with diabetic foot ulcer in some provinces of China. Chin J Diabetes Mellitus. 2014;6(7):July. doi:10.3760/cma.j.issn.1674-5809.2014.07.005
   Google Scholar
• Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–189. doi:10.1001/jama.295.2.180
   PubMed Web of Science ®Google Scholar
• Minqin R, Rajendran R, Pan N, et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med. 2005;38(9):1206–1211. doi:10.1016/j.freeradbiomed.2005.01.008
   Web of Science ®Google Scholar
• Lee HT, Chiu LL, Lee TS, et al. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J Biomed Sci. 2003;10(5):510–517. doi:10.1007/BF02256112
   Web of Science ®Google Scholar
• Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147–150. doi:10.1016/s0014-5793(00)01920-7
   PubMed Web of Science ®Google Scholar
• Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–7810. doi:10.1074/jbc.M008922200
   PubMed Web of Science ®Google Scholar
• Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2011;21(8):568–575. doi:10.1016/j.numecd.2010.01.003
   PubMed Web of Science ®Google Scholar
• Li H, Feng SJ, Su LL, et al. Serum hepcidin predicts uremic accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Chin Med J. 2015;128(10):1351–1357. doi:10.4103/0366-6999.156781
   Web of Science ®Google Scholar
• Kali A, Yayar O, Erdogan B, et al. Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients? Hemodial Int. 2016;20(2):191–197. doi:10.1111/hdi.12355
   Web of Science ®Google Scholar
• Wang X, Sheng L, Ye P, et al. The association between Hepcidin and arterial stiffness in a community-dwelling population. Lipids Health Dis. 2018;17:1. doi:10.1186/s12944-018-0866-6
   Web of Science ®Google Scholar
• Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord. 2009;9:34. doi:10.1186/1471-2261-9-34
   Web of Science ®Google Scholar
• Li X, Ding D, Zhang Y, et al. Associations of plasma hepcidin with mortality risk in patients with coronary artery disease. Oncotarget. 2017;8(65):109497–109508. doi:10.18632/oncotarget.22722
   Google Scholar
• Galesloot TE, Holewijn S, Kiemeney LA, et al. Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population. Arterioscler Thromb Vasc Biol. 2014;34(2):446–456. doi:10.1161/ATVBAHA.113.302381
   Web of Science ®Google Scholar
• Malhotra R, Wunderer F, Barnes HJ, et al. Hepcidin deficiency protects against atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(2):178–187. doi:10.1161/ATVBAHA.118.312215
   Web of Science ®Google Scholar
• Finn AV, Nakano M, Polavarapu R, et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012;59(2):166–177. doi:10.1016/j.jacc.2011.10.852
   PubMed Web of Science ®Google Scholar
• Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med. 2007;232(8):1014–1020. doi:10.3181/0703-MR-54
   Web of Science ®Google Scholar
• Saeed O, Otsuka F, Polavarapu R, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(2):299–307. doi:10.1161/atvbaha.111.240101
   PubMed Web of Science ®Google Scholar
• Qianru LI, Yuan JJ, Luo YF. Analysis of serum hepcidin levels and related factors in patients with diabetic lower extremity vascular disease and foot ulcer. J Chin Physician. 2021;12:674–678.
   Google Scholar
• Pereira C, Miname M, Makdisse M, Kalil Filho R, Santos RD. Association of peripheral arterial and cardiovascular diseases in familial hypercholesterolemia. Arq Bras Cardiol. 2014;103(2):118–123. doi:10.5935/abc.20140097
   PubMed Web of Science ®Google Scholar
• Madu AJ, Ughasoro MD. Anaemia of chronic disease: an in-depth review. Med Princ Pract. 2017;26:1–9. doi:10.1159/000452104
   PubMed Web of Science ®Google Scholar
• de Las Cuevas Allende R, Díaz de Entresotos L, Conde Díez S. Anaemia of chronic diseases: pathophysiology, diagnosis and treatment. Med Clin. 2021;156(5):235–242. doi:10.1016/j.medcli.2020.07.035
   Web of Science ®Google Scholar
• Liu M, Fan F, Liu B, et al. Joint effects of plasma homocysteine concentration and traditional cardiovascular risk factors on the risk of new-onset peripheral arterial disease. Diabetes Metab Syndr Obes. 2020;13:3383–3393. doi:10.2147/DMSO.S267122
   PubMed Web of Science ®Google Scholar
• Zaric BL, Obradovic M, Bajic V, Haidara MA, Jovanovic M, Isenovic ER. Homocysteine and hyperhomocysteinaemia. Curr Med Chem. 2019;26(16):2948–2961. doi:10.2174/0929867325666180313105949
   PubMed Web of Science ®Google Scholar
• Ndevahoma F, Mukesi M, Dludla PV, Nkambule BB, Nepolo EP, Nyambuya TM. Body weight and its influence on hepcidin levels in patients with type 2 diabetes: a systematic review and meta-analysis of clinical studies. Heliyon. 2021;7(3):e06429. doi:10.1016/j.heliyon.2021.e0649
   Web of Science ®Google Scholar